Availability of Insulin Lispro Injection to Treat Diabetes

This article originally appeared here.
Share this content:
The Humalog Junior KwikPen has not been studied in pediatric patients with type 2 diabetes.
The Humalog Junior KwikPen has not been studied in pediatric patients with type 2 diabetes.

The Humalog® Junior KwikPen® (insulin lispro injection; Eli Lilly), a prefilled, half-unit, rapid-acting disposable insulin pen, is expected to be available soon.

Approved in June 2017, the Humalog Junior KwikPen contains 3 mL of U-100 rapid-acting insulin lispro. It provides up to 30 units of insulin per injection, with the ability to titrate in half-unit increments. The new Junior KwikPen is lighter and smaller than other half-unit insulin pens. Humalog has not been studied in patients under 3 years of age; it has not been studied in pediatric patients with type 2 diabetes. 

Insulin lispro is a rapid-acting human insulin analog. Its primary activity is regulation of glucose metabolism. Insulin lowers blood glucose by stimulating peripheral glucose uptake by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulins inhibit lipolysis and proteolysis, and enhance protein synthesis.

Humalog Junior KwikPen U-100 will be available as 5-count cartons. The BD pen needles are recommended for use with Humalog Junior KwiKPen.

Reference

e-Pharm/alert listserve. Humalog® Junior KwikPen®. Accessed September 26, 2017.

You must be a registered member of Endocrinology Advisor to post a comment.

Sign Up for Free e-Newsletters

CME Focus